<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089397</url>
  </required_header>
  <id_info>
    <org_study_id>17-11-LUMIDIAL</org_study_id>
    <secondary_id>2018-A02276-49</secondary_id>
    <nct_id>NCT04089397</nct_id>
  </id_info>
  <brief_title>Light Therapy on Sleep Quality in Dialysis Patients</brief_title>
  <acronym>LUMIDIAL</acronym>
  <official_title>Randomized Open-label Trial Evaluating Light Therapy on Sleep Quality in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Annecy Genevois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Annecy Genevois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep disorders are common in dialysis patients. At present, the management of insomnia in
      patients with chronic renal failure is not significantly different from that of the general
      population, which focuses on the management of co-factors, sleep hygiene, and
      cognitive-behavioral therapy.

      Light therapy is a paramedical practice that involves exposing a patient to a light intensity
      greater than 5000 Lux (usually 10,000 Lux) for 30 minutes in the morning between 7:00 and
      8:30. Its impact is partly mediated by an improvement in the nycthemeral cycle of melatonin.

      Light therapy may improve sleep disorders and anxious-depressive elements as suggested in the
      literature. This technique has not yet been evaluated in dialysis patients, whereas easy to
      set up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sleep disorders are common in dialysis patients. Indeed, several studies have reported that
      the prevalence of these disorders is higher than that of the general population. At present,
      the management of insomnia in patients with chronic renal failure is not significantly
      different from that of the general population, which focuses on the management of co-factors,
      sleep hygiene, and cognitive-behavioral therapy.

      Light therapy is a paramedical practice that involves exposing a patient to a light intensity
      greater than 5000 Lux (usually 10,000 Lux) for 30 minutes in the morning between 7:00 and
      8:30. Its impact is partly mediated by an improvement in the nycthemeral cycle of melatonin.
      Light therapy has been studied in several pathologies. In the context of renal insufficiency,
      only one randomized study was conducted in renal transplant patients: out of 30 patients, the
      effect of light therapy regained an 11-minute increase in sleep latency, an earlier awakening
      of 24 minutes, and a gain in the DASS-21 depression score of 1.7 points while there was no
      improvement in his three parameters in the control group. Interest in light therapy has also
      been evaluated in seasonal and non-seasonal depression. In a meta-analysis of 458 patients,
      light therapy adjuvant use was as effective as the addition of a second molecule.

      Light therapy may improve sleep disorders and anxious-depressive elements as suggested in the
      literature. This technique has not yet been evaluated in dialysis patients, whereas easy to
      set up.

      We therefore wish to set up a clinical study to determine whether a light therapy technique
      in the morning during dialysis or at home improves the quality of sleep of chronic
      hemodialysis patients. The secondary objectives will be to specify the improved sleep
      parameters, to evaluate the impact on the anxious-depressive score, the arterial
      hypertension, and the nutritional state, and the residual effect of light therapy.

      The aim of this trial is to determine whether a light therapy technique in the morning during
      dialysis or at home improves the quality of sleep of chronic hemodialysis patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">May 11, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized open-label trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of light therapy on the quality of sleep of dialysis patients</measure>
    <time_frame>5 weeks</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) questionnaire is a self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.
The primary endpoint is the measured difference in PSQI score between baseline and 5 weeks post-exposure to light therapy between the two arms of the study (no light therapy versus active light therapy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological sleep disorders defined by PSQI score &gt; 5</measure>
    <time_frame>5 weeks</time_frame>
    <description>Percentage of patients with a PSQI score &gt; 5 measured in both arms at baseline and after 5 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of each component of the PSQI score</measure>
    <time_frame>5 weeks</time_frame>
    <description>There are 7 components in the PSQI score (sleep duration, sleep disturbance, sleep latency, daytime dysfunction due to sleepiness, sleep efficiency, overall sleep quality, and sleep medication use). Each of the sleep components yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction.
Difference of the medians obtained on each component of the PSQI score in both arms at baseline and after 5 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxious-depressive state of the patients</measure>
    <time_frame>5 weeks</time_frame>
    <description>The French Depression Anxiety Stress Scales (DASS 21) is a 21-item self-rated questionnaire designed to measure the emotional states of depression, anxiety and stress over the past week. The scale to which each item belongs is indicated by the letter D (Depression), A (Anxiety) and S (Stress). For each scale, scores are summed with the higher scores corresponding to the most severe status.
Total score difference obtained from the questionnaire French Depression Anxiety Stress Scales (DASS 21) in both arms at baseline and after 5 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of light therapy on nutritional intake of patients</measure>
    <time_frame>10 weeks</time_frame>
    <description>The normalized protein catabolic rate is a formula commonly used to assess dietary protein intake in dialysis patients, as a means towards determining nutritional adequacy.
Absolute difference in Normalized Protein Catabolic Rate value in both arms at baseline, after 5 weeks and 10 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure values</measure>
    <time_frame>10 weeks</time_frame>
    <description>Absolute difference in systolic blood pressure in both arms at baseline, after 5 weeks and 10 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure values</measure>
    <time_frame>10 weeks</time_frame>
    <description>Absolute difference in diastolic blood pressure in both arms at baseline, after 5 weeks and 10 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of light therapy</measure>
    <time_frame>5 weeks</time_frame>
    <description>Number and frequency of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of home care on the effectiveness of the primary endpoint</measure>
    <time_frame>5 weeks</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) questionnaire is a self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.
Difference in the average PSQI score between the two subgroups: home care versus during dialysis light therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the residual duration of the effect of light therapy on sleep disorder</measure>
    <time_frame>5 weeks</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) questionnaire is a self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.
Average difference in PSQI score at the end of the procedure and 5 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the residual duration of the effect of light therapy on anxious-depressive state of the patients</measure>
    <time_frame>5 weeks</time_frame>
    <description>The French Depression Anxiety Stress Scales (DASS 21) is a 21-item self-rated questionnaire designed to measure the emotional states of depression, anxiety and stress over the past week. The scale to which each item belongs is indicated by the letter D (Depression), A (Anxiety) and S (Stress). For each scale, scores are summed with the higher scores corresponding to the most severe status.
Average difference in DASS 21 score, at the end of the procedure and 5 weeks later.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Renal Failure</condition>
  <condition>Sleep Disorder</condition>
  <condition>Hemodialysis</condition>
  <condition>Light Therapy</condition>
  <arm_group>
    <arm_group_label>Light therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis (at home, for patients dialyzing the afternoon, or during dialysis for patients dialyzing in the morning)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care, without light therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light Therapy</intervention_name>
    <description>Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis</description>
    <arm_group_label>Light therapy group</arm_group_label>
    <other_name>Lumie BrazilÂ® (light therapy device for the treatment of seasonal affective disorders)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient in conventional hemodialysis or hemodiafiltration for at least 3 months

          -  Patient requiring a dialysis session three times a week in the investigational site

          -  Patient benefiting from a social security scheme

          -  Patient informed and having given his free and informed consent to participate in the
             study

        Exclusion Criteria:

          -  Patient with binocular blindness and / or age-related macular degeneration

          -  Eye fatigue

          -  Patient who has undergone a recent eye surgery (less than 3 months) or for whom such
             an operation is planned in the next 20 weeks

          -  Patient taking medications known to be responsible for photosensitivity

          -  Pregnant or lactating woman

          -  Patient under guardianship or curatorship

          -  Patient unable to give free and informed consent

        Exclusion during the study - premature stop

          -  Wishes of the patient or the physician

          -  Appearance of unexplained visual disturbances

          -  Kidney transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Franko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Annecy Genevois</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Noret, PM</last_name>
    <phone>+33456497240</phone>
    <email>mnoret@ch-annecygenevois.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascale Cony-Makhoul, MD</last_name>
    <phone>+33450636431</phone>
    <email>pconymakhoul@ch-annecygenevois.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Noret, PM</last_name>
      <phone>+33456497240</phone>
      <email>mnoret@ch-annecygenevois.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pascale Cony-Makhoul, MD</last_name>
      <phone>+33450636431</phone>
      <email>pconymakhoul@ch-annecygenevois.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Benoit Franko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>light therapy in sleep disorders of dialysis patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

